Zydus Lifesciences Ltd (ZYDUSLIFE) — shareholding pattern, promoter holding, financials and share price

Zydus Lifesciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ZYDUSLIFE and on the BSE under scrip code 532321. Its ISIN is INE010B01027.

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Zydus Lifesciences Limited is an innovation-driven, vertically integrated pharmaceutical group operating across generics, branded formulations, biosimilars, vaccines, APIs, consumer wellness and MedTech, with ~41 manufacturing sites, eight R&D centres, and global revenues around $2.75 billion, positioning the company as a major Indian pharma exporter and a top generics player in the US.

Q3 FY26 financials show robust execution: consolidated revenues of Rs. 68,645 mn (▲30% YoY), EBITDA of Rs. 18,164 mn (26.5% margin), R&D spend at 8.8% of revenues, and adjusted net profit of Rs. 11,109 mn; organic capex remains high at Rs. 4,637 mn for the quarter, while net debt widened to Rs. 28,728 mn at quarter end.

Listed peers in Pharmaceuticals: Cipla Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.